Subscribe to RSS
DOI: 10.1055/a-1749-2969
Kann Diabetes durch COVID-19 ausgelöst werden?
Erkenntnisse fast 2 Jahre nach Beginn der PandemieZUSAMMENFASSUNG
Es wurde lange diskutiert, ob COVID-19 zu neu auftretendem Diabetes führen kann. Jedoch jetzt, fast 2 Jahre nach Beginn der Pandemie, haben mehrere Studien berichtet, dass neu auftretender Diabetes mit COVID-19 in Verbindung gebracht wird. Stoffwechselerkrankungen sind mit einem erhöhten Risiko für schweres COVID-19 verbunden und umgekehrt wurden bei COVID-19-Patienten eine neu auftretende Hyperglykämie und Komplikationen eines vorbestehenden Diabetes beobachtet. Darüber hinaus sind leicht erhöhte Blutzuckerwerte bei COVID-19-Patienten selbst bei Menschen ohne Diabetes mit schlechteren Ergebnissen verbunden. Die genauen Mechanismen für einen neu auftretenden Diabetes bei Patienten mit COVID-19 sind noch nicht bekannt. Wahrscheinlich handelt es sich neben direkten oder indirekten Auswirkungen von SARS-CoV-2 auf die Beta-Zellen in der Bauchspeicheldrüse um eine Reihe komplexer zusammenhängender Prozesse, so wie zuvor nicht diagnostizierter Diabetes, Stresshyperglykämie und steroidinduzierte Hyperglykämie.
Publication History
Article published online:
24 February 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Bornstein SR, Dalan R, Hopkins D. et al Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol 2020; 16: 297-298 DOI: 10.1038/s41574-020-0353-9.
- 2 Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. J Endocrinol Invest 2020; 43: 1027-1031 DOI: 10.1007/s40618-020-01276-8.
- 3 Somasundaram NP, Ranathunga I, Ratnasamy V. et al The Impact of SARS-Cov-2 Virus Infection on the Endocrine System. J Endocr Soc 2020; 4: bvaa082 DOI: 10.1210/jendso/bvaa082.
- 4 Steenblock C, Todorov V, Kanczkowski W. et al Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis. Mol Psychiatry 2020; 25: 1611-1617 DOI: 10.1038/s41380-020-0758-9.
- 5 Steenblock C, Schwarz PEH, Ludwig B. et al COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol 2021; 9: 786-798 DOI: 10.1016/S2213-8587(21)00244-8.
- 6 Zhu L, She ZG, Cheng X. et al Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 2020; 31: 1068-1077 e3 DOI: 10.1016/j.cmet.2020.04.021.
- 7 Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, Klonoff DC. (2020) Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol 14: 813-821 DOI: 10.1177/1932296820924469.
- 8 Li H, Tian S, Chen T, Cui Z, Shi N. et al Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab 2020; 22: 1897-1906 DOI: 10.1111/dom.14099.
- 9 Alsadhan I, Alruwashid S, Alhamad M. et al Diabetic ketoacidosis precipitated by Coronavirus disease 2019 infection: Case series. Curr Ther Res Clin Exp 2020; 93: 100609 DOI: 10.1016/j.curtheres.2020.100609.
- 10 Chee YJ, Ng SJH, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract 2020; 164: 108166 DOI: 10.1016/j.diabres.2020.108166.
- 11 Goldman S, Pinhas-Hamiel O, Weinberg A. et al Alarming increase in ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the first wave of the COVID-19 pandemic in Israel. Pediatr Diabetes 2021; 23: 10-18 DOI: 10.1111/pedi.13296.
- 12 Heaney AI, Griffin GD and Simon EL. Newly diagnosed diabetes and diabetic ketoacidosis precipitated by COVID-19 infection. Am J Emerg Med 2020; 38: 2491 e3-2491 e4 DOI: 10.1016/j.ajem.2020.05.114.
- 13 Hollstein T, Schulte DM, Schulz J. et al Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nat Metab 2020; 2: 1021-1024 DOI: 10.1038/s42255-020-00281-8.
- 14 Li J, Wang X, Chen J. et al COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 2020; 22: 1935-1941 DOI: 10.1111/dom.14057.
- 15 Naguib MN, Raymond JK, Vidmar AP. New onset diabetes with diabetic ketoacidosis in a child with multisystem inflammatory syndrome due to COVID-19. J Pediatr Endocrinol Metab 2021; 34: 147-150 DOI: 10.1515/jpem-2020-0426.
- 16 Trieu C, Sunil B, Ashraf AP. et al SARS-CoV-2 infection in hospitalized children with type 1 and type 2 diabetes. J Clin Transl Endocrinol 2021; 26: 100271 DOI: 10.1016/j.jcte.2021.100271.
- 17 Rubino F, Amiel SA, Zimmet P. et al New-Onset Diabetes in Covid-19. N Engl J Med 2020; 383: 789-790 DOI: 10.1056/NEJMc2018688.
- 18 Unsworth R, Wallace S, Oliver NS. et al New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care 2020; 43: e170-e171 DOI: 10.2337/dc20-1551.
- 19 McGlacken-Byrne SM, Drew SEV, Turner K. et al The SARS-CoV-2 pandemic is associated with increased severity of presentation of childhood onset type 1 diabetes mellitus: A multi-centre study of the first COVID-19 wave. Diabet Med 2021; 38: e14640 DOI: 10.1111/dme.14640.
- 20 Tittel SR, Rosenbauer J, Kamrath C. et al Initiative DPV. Did the COVID-19 Lockdown Affect the Incidence of Pediatric Type 1 Diabetes in Germany?. Diabetes Care 2020; 43: e172-e173 DOI: 10.2337/dc20-1633.
- 21 Kamrath C, Monkemoller K, Biester T. et al Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic in Germany. JAMA 2020; 324: 801-804 DOI: 10.1001/jama.2020.13445.
- 22 Accili D. Can COVID-19 cause diabetes?. Nat Metab 2021; 3: 123-125 DOI: 10.1038/s42255-020-00339-7.
- 23 Armeni E, Aziz U, Qamar S. et al Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series. Lancet Diabetes Endocrinol 2020; 8: 660-663 DOI: 10.1016/S2213-8587(20)30221-7.
- 24 Pasquel FJ, Messler J, Booth R. et al Characteristics of and Mortality Associated With Diabetic Ketoacidosis Among US Patients Hospitalized With or Without COVID-19. JAMA Netw Open 2021; 4: e211091 DOI: 10.1001/jamanetworkopen.2021.1091.
- 25 Khunti K, Del Prato S, Mathieu C. et al COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care 2021; 44: 2645-2655 DOI: 10.2337/dc21-1318.
- 26 Sathish T, Kapoor N, Cao Y. et al Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab 2021; 23: 870-874 DOI: 10.1111/dom.14269.
- 27 Coppelli A, Giannarelli R, Aragona M. et al Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. Diabetes Care 2020; 43: 2345-2348 DOI: 10.2337/dc20-1380.
- 28 Coate KC, Cha J, Shrestha S. et al SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are Not Enriched in beta Cells. Cell Metab 2020; 32: 1028-1040 e4 DOI: 10.1016/j.cmet.2020.11.006.
- 29 Kusmartseva I, Wu W, Syed F. et al Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19. Cell Metab 2020; 32: 1041-1051 e6 DOI: 10.1016/j.cmet.2020.11.005.
- 30 Liu F, Long X, Zhang B. et al ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol 2020; 18: 2128-2130 e2 DOI: 10.1016/j.cgh.2020.04.040.
- 31 Steenblock C, Richter S, Berger I. et al Viral infiltration of pancreatic islets in patients with COVID-19. Nat Commun 2021; 12: 3534 DOI: 10.1038/s41467-021-23886-3.
- 32 Oray M, Abu Samra K, Ebrahimiadib N. et al Long-term side effects of glucocorticoids. Expert Opin Drug Saf 2016; 15: 457-465 DOI: 10.1517/14740338.2016.1140743.
- 33 Wang S, Ma P, Zhang S. et al Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia 2020; 63: 2102-2111 DOI: 10.1007/s00125-020-05209-1.
- 34 Muller JA, Gross R, Conzelmann C. et al SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab 2021; 3: 149-165 DOI: 10.1038/s42255-021-00347-1.
- 35 Qadir MMF, Bhondeley M, Beatty W. et al SARS-CoV-2 infection of the pancreas promotes thrombofibrosis and is associated with new-onset diabetes. JCI Insight 2021: 6 DOI: 10.1172/jci.insight.151551
- 36 Zinserling VA, Bornstein SR, Narkevich TA. et al Stillborn child with diffuse SARS-CoV-2 viral infection of multiple organs. IDCases 2021; 26: e01328 DOI: 10.1016/j.idcr.2021.e01328.
- 37 Hoffmann M, Kleine-Weber H, Schroeder S. et al SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181: 271-280 e8 DOI: 10.1016/j.cell.2020.02.052.
- 38 Fignani D, Licata G, Brusco N. et al SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic beta-Cells and in the Human Pancreas Microvasculature. Front Endocrinol (Lausanne) 2020; 11: 596898 DOI: 10.3389/fendo.2020.596898.
- 39 Murphy JM, Czabotar PE, Hildebrand JM. et al The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 2013; 39: 443-53 DOI: 10.1016/j.immuni.2013.06.018.
- 40 Sun L, Wang H, Wang Z. et al Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148: 213-227 DOI: 10.1016/j.cell.2011.11.031.
- 41 Gong YN, Guy C, Olauson H. et al ESCRT-III Acts Downstream of MLKL to Regulate Necroptotic Cell Death and Its Consequences. Cell 2017; 169: 286-300 e16 DOI: 10.1016/j.cell.2017.03.020.
- 42 Meessen-Pinard M, Le Coupanec A, Desforges M, Talbot PJ. Pivotal Role of Receptor-Interacting Protein Kinase 1 and Mixed Lineage Kinase Domain-Like in Neuronal Cell Death Induced by the Human Neuroinvasive Coronavirus OC43. J Virol 2017: 91 DOI: 10.1128/JVI.01513-16
- 43 Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015; 517: 311-20 DOI: 10.1038/nature14191.
- 44 Linkermann A, Green DR. Necroptosis. N Engl J Med 2014; 370: 455-465 DOI: 10.1056/NEJMra1310050.
- 45 Geravandi S, Mahmoudi-Aznaveh A, Azizi Z. et al SARS-CoV-2 and pancreas: a potential pathological interaction?. Trends Endocrinol Metab 2021; 32: 842-845 DOI: 10.1016/j.tem.2021.07.004.
- 46 Kuchay MS, Reddy PK, Gagneja S. et al Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19. Diabetes Metab Syndr 2020; 14: 2039-2041 DOI: 10.1016/j.dsx.2020.10.015.
- 47 Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2020; 47: 193-199 DOI: 10.1007/s00592-009-0109-4.
- 48 Ghosh A, Anjana RM, Shanthi Rani CS. et al Glycemic parameters in patients with new-onset diabetes during COVID-19 pandemic are more severe than in patients with new-onset diabetes before the pandemic: NOD COVID India Study. Diabetes Metab Syndr 2021; 15: 215-220 DOI: 10.1016/j.dsx.2020.12.033.
- 49 Maestre-Muniz MM, Arias A, Mata-Vazquez E. et al Long-Term Outcomes of Patients with Coronavirus Disease 2019 at One Year after Hospital Discharge. J Clin Med 2021: 10 DOI: 10.3390/jcm10132945
- 50 Montefusco L, Ben Nasr M, D’Addio F, Loretelli C, Rossi A, Pastore I, Daniele G, Abdelsalam A, Maestroni A, Dell’Acqua M, Ippolito E, Assi E, Usuelli V, Seelam AJ, Fiorina RM, Chebat E, Morpurgo P, Lunati ME, Bolla AM, Finzi G, Abdi R, Bonventre JV, Rusconi S, Riva A, Corradi D, Santus P, Nebuloni M, Folli F, Zuccotti GV, Galli M, Fiorina P. 2021; Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab 3: 774-785 DOI: 10.1038/s42255-021-00407-6.
- 51 Laurenzi A, Caretto A, Molinari C. et al No evidence of long-term disruption of glycometabolic control after SARS-CoV-2 infection. J Clin Endocrinol Metab 2021: dgab792 DOI: 10.1210/clinem/dgab792
- 52 Brosh-Nissimov T, Orenbuch-Harroch E. et al BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect 2021; 27: 1652-1657 DOI: 10.1016/j.cmi.2021.06.036.